Natera

NTRA

Market cap $30.6B

It's hard to pick just one favorite stock idea for the rest of the year. It's been a blistering-hot 2026, as the AI revolution keeps rolling ahead.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As part of the collaboration, Signatera will be used to longitudinally assess molecular response in patients with refractory melanoma enrolled in Diakonos' DOC-RM Phase I/II investigational immunotherapy.

NTRA upgrades Panorama NIPT with SNP-informed deep sequencing, validated for low fetal fraction to cut no-calls and boost reliable prenatal results.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first patients in SIgnatera-Guided iNterventionAL (SIGNAL)-ER 101, a prospective, single-arm, multi-center study evaluating Signatera MRD-guided de-escalation in early-stage breast cancer. The current standard of care recommends two or three years of an adjuvant CDK4/6 inhibitor in combination with endocrine therapy for patients with intermediat.

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.

Natera gets buy rating reaffirmed, driven by robust expansion plans, recent FDA approval, and upgraded FY26 revenue guidance. NTRA's Q1 revenue grew 38% YoY, with test volumes up 18.5%, reflecting strong operational momentum and market demand. Despite ongoing unprofitability, margin improvements and analyst consensus point toward profitability by FY28, supported by upward earnings revisions.

NTRA is expanding in Austin with what it says will be the world's largest sequencing capacity as oncology testing demand keeps surging.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive prenatal test (NIPT). Powered by the company's novel SNP-informed deep sequencing technology, Panorama NIPT is now backed by clinically-validated performance data in samples with low fetal fraction, enabling a no-call rate of 0.5%. Fetal fraction refers to the proportion of placental DNA circulating.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place May 29–June 2 in Chicago, IL. Together with its collaborators, Natera will demonstrate unmatched scale in evidence generation with 35 abstracts across molecular residual disease (MRD) testing and other innovations. Presentations w.

NTRA's EXPAND trial for Fetal Focus single-gene NIPT tops 2,000 patients, doubling in a year as new data spotlight its robust design.